AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| AbbVie (NYSE: ABBV) | Delayed: 285.19 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $285.19 | 52 Week High | $68.12 | |||
| Open | $285.19 | 52 Week Low | $50.71 | |||
| Day High | $285.19 | P/E | 61.86 | |||
| Day Low | $285.19 | EPS | $4.61 | |||
| Volume | 139 | |||||
